Establishment Labs Holdings Inc. (NASDAQ:ESTA) Principal shareholder acquires $2,450,350.00 in stock


Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Rating) principal shareholder Jw Asset Management, Llc purchased 35,000 shares in a trade on Wednesday, April 13. The shares were purchased at an average price of $70.01 per share, for a total transaction of $2,450,350.00. Following the purchase, the insider now directly owns 3,177,485 shares of the company, valued at approximately $222,455,724.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this hyperlink. Large shareholders who own more than 10% of a company’s stock are required to disclose their sales and purchases to the SEC.

Jw Asset Management, Llc also recently completed the following transactions:

  • On Monday, March 14, Jw Asset Management, Llc purchased 10,000 shares of Establishment Labs. The shares were purchased at an average cost of $52.63 per share, with a total value of $526,300.00.
  • On Wednesday, March 2, Jw Asset Management, Llc acquired 5,000 shares of Establishment Labs. The shares were purchased at an average cost of $59.45 per share, with a total value of $297,250.00.
  • On Monday, February 28, Jw Asset Management, Llc acquired 10,000 shares of Establishment Labs. The shares were purchased at an average cost of $59.42 per share, with a total value of $594,200.00.

ESTA shares opened at $71.87 on Friday. Establishment Labs Holdings Inc. has a fifty-two week low of $46.93 and a fifty-two week high of $88.66. The company has a debt ratio of 1.02, a quick ratio of 2.66 and a current ratio of 3.55. The stock’s 50-day simple moving average is $60.50 and its 200-day simple moving average is $63.95.

Establishment Labs (NASDAQ:ESTA – Get Rating) last released its quarterly results on Tuesday, March 1. The company reported ($0.60) earnings per share for the quarter, missing the Zacks consensus estimate of ($0.33) by ($0.27). Establishment Labs had a negative return on equity of 64.87% and a negative net margin of 32.47%. During the same period of the previous year, the company posted an EPS of ($0.23). Stock analysts expect Establishment Labs Holdings Inc. to post -1.27 earnings per share for the current fiscal year.

Major investors have recently changed their positions in the company. Macquarie Group Ltd. acquired a new position in Establishment Labs in the third quarter worth approximately $38,000. Deutsche Bank AG increased its position in shares of Establishment Labs by 120.5% during the third quarter. Deutsche Bank AG now owns 679 shares of the company worth $49,000 after buying 371 more shares last quarter. Advisor Group Holdings Inc. increased its position in shares of Establishment Labs by 502.7% during the third quarter. Advisor Group Holdings Inc. now owns 904 shares of the company worth $65,000 after purchasing an additional 754 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Establishment Labs during the second quarter for a value of approximately $180,000. Finally, Parametric Portfolio Associates LLC purchased a new stake in shares of Establishment Labs during the second quarter for a value of approximately $206,000. 68.57% of the shares are held by institutional investors.

ESTA has been the subject of several analyst reports. Goldman Sachs Group lowered its price target on Establishment Labs from $78.00 to $67.00 and set a “neutral” rating for the company in a Monday, March 21 research report. Zacks Investment Research downgraded Establishment Labs from a “hold” rating to a “sell” rating in a Friday, March 4 research note. One research analyst has rated the security with a sell rating, one has issued a hold rating and three have issued a buy rating for the security. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $84.40.

Establishment Labs Company Profile (Get a rating)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for cosmetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 soft silicone gel filled round breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, and also distributes the Puregraft line of products for the harvesting and redistribution of autologous adipose tissue.

Further reading

Insider Buying and Selling by Quarter for Establishment Labs (NASDAQ:ESTA)



Receive daily news and reviews for facility labs – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Establishment Labs and related companies with MarketBeat.com’s FREE daily newsletter.

Comments are closed.